Epithalamin (Epithalon Bioregulator)

Epithalamin is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG) with a molecular weight of approximately 390 Da, originally isolated from bovine pineal gland extracts. It represents the active bioregulatory peptide produced by the pineal gland that declines with age as the pineal undergoes progressive calcification. Prof. Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology has studied this peptide for over 35 years, and the compound is also referred to as Epithalon or Epitalon in various publications.

The primary mechanism of action is activation of telomerase, the ribonucleoprotein enzyme complex (consisting of the catalytic subunit hTERT and the RNA template hTR/TERC) that synthesizes TTAGGG hexanucleotide repeats at chromosome ends (telomeres). Telomere shortening is recognized as one of the nine hallmarks of aging defined by Lopez-Otin et al. (Cell, 2013). Each cell division erodes approximately 50-100 base pairs from telomere ends due to the end-replication problem. When telomeres shorten below a critical threshold (~4 kilobases), cells enter replicative senescence or apoptosis, contributing to tissue aging and dysfunction. By upregulating hTERT transcription, epithalamin allows cells to maintain telomere length and extend their replicative capacity.

In human pulmonary fibroblast cultures, epithalamin increased telomerase activity by 2.4-fold as measured by the TRAP (Telomeric Repeat Amplification Protocol) assay and extended the replicative lifespan of the cells by 44%, surpassing the Hayflick limit (normally 50-60 population doublings). In animal longevity studies, epithalamin extended maximum lifespan by 13% in CBA mice, 25% in female SHR rats, 16% in Drosophila melanogaster, and 15-20% in C. elegans nematodes. These studies were published in Mechanisms of Ageing and Development and Bulletin of Experimental Biology and Medicine.

The most compelling evidence comes from human clinical studies. A prospective study of 266 elderly patients (age 60-74) in St. Petersburg, followed for 12 years, showed that those treated with epithalamin (in combination with thymalin) had significantly reduced mortality compared to untreated controls. Treated patients showed normalized circadian melatonin rhythms, improved immune function (restored CD4/CD8 ratios, NK cell activity), and reduced incidence of ischemic heart disease, hypertension, osteoporosis, and respiratory infections.

Epithalamin also acts on the pineal gland to restore melatonin synthesis. It upregulates the rate-limiting enzyme AANAT (arylalkylamine N-acetyltransferase) in pinealocytes, restoring the nocturnal melatonin surge that declines with age. This has downstream effects on circadian rhythm, antioxidant protection (melatonin is a potent free radical scavenger), immune function (melatonin receptors are expressed on T-cells and NK cells), and sleep architecture.

Pharmacokinetically, the tetrapeptide is absorbed rapidly after subcutaneous injection, with peak plasma levels at 15-30 minutes. As a small tetrapeptide, it crosses biological membranes readily and reaches target tissues including the pineal gland. The biological effects of a 10-day course persist for 4-6 months, reflecting the gene-regulatory mechanism (epigenetic modification of hTERT promoter) rather than simple receptor agonism. Oral bioavailability has not been formally characterized, but the bioregulator capsule form is used clinically in Russia.

Storage and handling: lyophilized epithalamin should be stored at -20C for long-term stability or 2-8C for up to 90 days. Reconstitute with bacteriostatic water or sterile 0.9% saline. Reconstituted solutions should be kept at 2-8C and used within 14-21 days. The peptide is stable at pH 4-7. Protect from light and avoid repeated freeze-thaw cycles.

Safety data spans over 35 years of research and clinical use in Russia. No serious adverse events have been attributed to epithalamin in published studies. The peptide has been administered to thousands of elderly patients in clinical studies with no reported toxicity, immunogenicity, or carcinogenicity. Importantly, telomerase activation by epithalamin occurs in normal somatic cells, restoring their replicative capacity, and is distinct from the constitutive telomerase activation seen in cancer cells, which is driven by hTERT gene amplification or promoter mutations, not by the bioregulatory mechanism through which epithalamin operates.